Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026)
Pharvaris (PHVS) posted Long-Term Deferred Tax of $875169.8 for Q1 2026, down 15.27% on a QoQ basis from $1.0 million in Q4 2025, and up 123.46% year-over-year from $391638.7 in Q1 2025.
Pharvaris (PHVS) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Pharvaris' Long-Term Deferred Tax history runs 7 years deep, the most recent figure standing at $875169.8 for Q1 2026.
- Quarterly Long-Term Deferred Tax rose 123.46% year-over-year to $875169.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $875169.8 (up 123.46% YoY) and the FY2025 annual result came in at $1.0 million, up 95.27% from the prior year.
- Long-Term Deferred Tax was $875169.8 for Q1 2026 at Pharvaris, down from $1.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $1.0 million in Q4 2025 and bottomed at $96667.3 in Q1 2023.
- A 5-year average of $385868.2 and a median of $337180.2 in 2025 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax slumped 36.97% — and 2024, when it soared 345.14%.
- Pharvaris' Long-Term Deferred Tax stood at $265063.3 in 2022, then soared by 57.31% to $416957.9 in 2023, then gained by 21.57% to $506885.0 in 2024, then soared by 103.78% to $1.0 million in 2025, then retreated by 15.27% to $875169.8 in 2026.
- Business Quant data shows PHVS's Long-Term Deferred Tax at $875169.8 in Q1 2026, $1.0 million in Q4 2025, and $535260.1 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 875,169.84 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 535,260.06 |
| Jun 30, 2025 | 337,180.23 |
| Mar 31, 2025 | 391,638.67 |
| Dec 31, 2024 | 506,885.02 |
| Sep 30, 2024 | 267,827.18 |
| Jun 30, 2024 | 373,271.85 |
| Mar 31, 2024 | 430,304.64 |
| Dec 31, 2023 | 416,957.92 |
| Sep 30, 2023 | 329,461.91 |
| Jun 30, 2023 | 199,831.78 |
| Mar 31, 2023 | 96,667.31 |
| Dec 31, 2022 | 265,063.33 |
| Sep 30, 2022 | 241,413.14 |
| Jun 30, 2022 | 106,547.74 |
| Mar 31, 2022 | 153,362.96 |
| Dec 31, 2021 | 196,823.63 |
| Sep 30, 2021 | 138,139.36 |
| Jun 30, 2021 | 123,526.94 |